NORTHVALE, N.J., Sept. 14, 2017 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (ADMT) announced that OneMed Research has issued an investment report on ADMT.
Andre' DiMino, ADMT President, stated, "We are pleased OneMed's report focuses on our efforts at advancing our proprietary medical device technologies. We are close to the launch of Tinnitus Shield and continue to work on development of our next two medical technologies, Aurex-3 and Sonotron. We believe the success of any of these technologies can bring our Company to the next level."
Prepared by OneMed Research
ADM Tronics Unlimited, Inc.
Sector: Medical Device
Area: Tinnitus, Pain Management
Vertically-integrated, medical device firm introducing innovative pain and Tinnitus products
ADM Tronics Unlimited, Inc. has developed innovative technologies to address two market opportunities: Tinnitus and pain.
Tinnitus. ADMT has two products geared toward Tinnitus, a condition commonly described as "ringing in the ears". The first, Tinnitus Shield is intended to prevent the onset of Tinnitus. It consists of a patent-pending membrane earplug the user wears, blocking out frequencies that may cause Tinnitus, still allowing the user to hear normal conversation and sounds. Its second product, Aurex-3, is an electronic therapy device that applies vibratory pulses against the mastoid bone behind the ear where the cochlea is located, affecting the chamber of the ear containing the nerves that allow one to hear. The product is tuned to each patient enabling them to treat and control Tinnitus and incorporates digital control, allowing for smartphone, tablet and cloud integration, to wirelessly monitor and forward patient progress directly to their physician to improve patient usability and compliance.
Pain. ADMT's product focused on pain is the Sonotron, a non-invasive, electro-therapy device that applies a pulsed long-wave radio frequency to painful joints for the treatment of pain, including osteoarthritis.
The US Veterans Administration ("VA") reports that Tinnitus is the most prevalent combat-related disability affecting veterans. The Center for Disease Control estimates over 45 million Americans experience some form of Tinnitus. There are currently no truly effective treatments for this condition.
The pain market is vast and is seeking alternatives to opioids which have great danger of addiction and risk of death by overdose. The Company's development of a non-invasive safe technology for joint pain represents a very large opportunity.
Company has been profitable for 16 consecutive quarters providing its design services as an OEM to leading device companies. It is now transitioning into bringing proprietary technologies to address two very large markets: Tinnitus and pain.
- Launch of Tinnitus Shield Product - October 2017
- New filing of the Aurex-3 with the FDA – Early 2018
- Introduction of the Aurex-3
- FDA Filing of the Sonotron Electrotherapy device
Risk Factors/ Competitors
ADMT is unique in its vertical integration to bring ideas from concept to commercialization in the development of medical technologies. In the Tinnitus marketplace there are no known cures, despite a variety of companies developing solutions. In the pain market, there are a variety of approaches ranging from drugs to treatments, but no firm has developed a solution such as offered by the Company combining a radio frequency wave pulsed at a sound wave rate.
ADMT was founded in 1969, by the current CEO's father, Dr. Alfonso DiMino. Since its founding the Company has provided design and engineering, regulatory and manufacturing services to a wide range of medical device companies. It has also developed proprietary technologies which it is now commercializing.
Company's multi-disciplinary in-house team of researchers, designers, engineers, regulatory and manufacturing experts bring diagnostic and therapeutic medical technologies from concept through production.
The Company has been consistently profitable generating enough free cash to fund developments of its products.
The Aurex was previously FDA-cleared and the Sonotron was distributed in overseas markets. The Company has re-engineered both and expecting FDA clearance for the updated versions of these devices.
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact: Andre' DiMino 201-767-6040, email@example.com